Michela Giustozzi1, Hussam Ali2,3, Gianpaolo Reboldi4, Cristina Balla5, Sara Foresti2,3, Guido de Ambroggi2,3, Pier Paolo Lupo2,3, Giancarlo Agnelli1, Riccardo Cappato6,7. 1. Vascular and Emergency Medicine and Stroke Unit, University of Perugia, Perugia, Italy. 2. Arrhythmia and Electrophysiology Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. 3. Italy Gavazzeni Hospital, Second Arrhythmia and EP Unit, Bergamo, Italy. 4. Department of Medicine, University of Perugia, Perugia, Italy. 5. Cardiovascular Institute, Azienda Ospedaliero-Universitaria S. Anna, Cona, FE, Italy. 6. Arrhythmia and Electrophysiology Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. riccardo.cappato@hunimed.eu. 7. Italy Gavazzeni Hospital, Second Arrhythmia and EP Unit, Bergamo, Italy. riccardo.cappato@hunimed.eu.
Abstract
PURPOSE: In patients with cancer, the safety of catheter ablation for non-valvular atrial fibrillation (AF) has not been evaluated, yet. The aim of this study was to assess the safety of AF ablation in cancer survivors. METHODS: Consecutively recruited patients undergoing catheter ablation of non-valvular AF at our center between March 2015 and March 2017 were evaluated. The primary outcome of the study was clinically relevant bleedings occurred within 30 ± 5 days after the procedure. Patients with cancer were propensity matched to patients without cancer in a 1:3 and 1:6 ratio after stratification by baseline clinical features. RESULTS: Overall, 184 patients were included in the study. Of them, 21 (11%) were cancer survivors. Cancer site was more frequently gastrointestinal (36%), breast (23%), and genitourinary (18%). At 30 ± 5 days, clinically relevant bleedings occurred in 14 patients. Crude odds ratio (OR) for clinically relevant bleedings was 3.60 (95% CI 1.02-12.7) higher in cancer than in non-cancer patients. This trend remained after propensity score-matched population (OR 3.48, 95% CI 0.76-15.90 for matched 1:3, OR 4.95, 95% CI 1.2-20.2 for matched 1:6). Type of anticoagulation was not associated with bleedings. CONCLUSIONS: Preliminary results suggest that clinically relevant bleeding after catheter ablation for AF is more frequent in cancer survivors than in patients without cancer. Further studies are required to confirm the present data.
PURPOSE: In patients with cancer, the safety of catheter ablation for non-valvular atrial fibrillation (AF) has not been evaluated, yet. The aim of this study was to assess the safety of AF ablation in cancer survivors. METHODS: Consecutively recruited patients undergoing catheter ablation of non-valvular AF at our center between March 2015 and March 2017 were evaluated. The primary outcome of the study was clinically relevant bleedings occurred within 30 ± 5 days after the procedure. Patients with cancer were propensity matched to patients without cancer in a 1:3 and 1:6 ratio after stratification by baseline clinical features. RESULTS: Overall, 184 patients were included in the study. Of them, 21 (11%) were cancer survivors. Cancer site was more frequently gastrointestinal (36%), breast (23%), and genitourinary (18%). At 30 ± 5 days, clinically relevant bleedings occurred in 14 patients. Crude odds ratio (OR) for clinically relevant bleedings was 3.60 (95% CI 1.02-12.7) higher in cancer than in non-cancerpatients. This trend remained after propensity score-matched population (OR 3.48, 95% CI 0.76-15.90 for matched 1:3, OR 4.95, 95% CI 1.2-20.2 for matched 1:6). Type of anticoagulation was not associated with bleedings. CONCLUSIONS: Preliminary results suggest that clinically relevant bleeding after catheter ablation for AF is more frequent in cancer survivors than in patients without cancer. Further studies are required to confirm the present data.
Authors: Avirup Guha; Anubhav Jain; Ankita Aggarwal; Amit K Dey; Sourbha Dani; Sarju Ganatra; Francis E Marchlinski; Daniel Addison; Michael G Fradley Journal: BMC Cardiovasc Disord Date: 2022-06-17 Impact factor: 2.174